The focus of HIV DART 2012 is to assemble clinicians, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in antiretroviral research. HIV DART 2012 will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection.
Conference Program Highlights
The conference program includes sessions covering the following topics:
• Drug Discovery and Development: Viral Targets
• Drug Design: Biochemistry & Mechanism
• Structural Biology & New Drug Development
• Immunotherapy & Vaccines for HIV Infection
• First-line Antiretroviral/Salvage Therapy
• Complications of Antiretroviral Therapy: Basic to Clinical
• HIV/Hepatitis and Other Co-infections
• Assessing the Benefits or Damages of Treatment Interruptions
Conference Objectives
HIV DART was designed to interest physicians, clinicians, scientists and clinical researchers in the HIV/co-infection arena.
The educational objectives of this program are as follows:
• Understand drug discovery and development, novel therapeutic agents, and viral targets for retroviruses
• Develop improved strategies to reduce or eliminate drug-resistance and toxicity
• Understand reservoirs and viral persistence towards HIV eradication
• Develop microbicides and other preventative approaches
• Understand the consequences of hepatitis co-infection on the management of HIV-infected individuals
• Provide insights on novel immunological approaches compatible with clinical drug development
• Develop targeted approaches to improve the pharmacology of antiretroviral agents
• Understand HIV therapy in pediatrics and the aging population
Target Audience
The Conference is open to anyone interested in HIV therapeutics. However, the content of this Conference was developed to interest primarily physicians, clinicians, scientists, nurses and clinical researchers in infectious diseases.
Official Language
English will be used throughout the Conference. Simultaneous translations will not be made available.
|
